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Introduction
Epstein-Barr virus (EBV) is a human herpesvirus of in-
creasing medical importance. EBV infection is associated 
with the development of nasopharyngeal carcinoma (NPC) 
and Burkitt’s lymphoma (BL). In addition, EBV infection is 
an important cause of lymphomas in severely immunocom-
promised persons, especially patients with AIDS and organ-
transplant recipients (Kieff, 1996; Pagano, 1991; Pagano, 
1999; Raab-Traub, 1996; Rickinson and Kieff, 1996).
The biologic hallmark of the EBV–lymphocyte interac-
tion is latency. Three types of latency have been described, 
each having its own distinct pattern of gene expression. 
Type I latency is exemplified by BL tumors in vivo and ear-
lier passages of cultured cell lines derived from BL biopsies. 
EBNA1 is the major viral protein synthesized in this form of 
latency. Latent membrane protein 2A (LMP2A) may also be 
expressed. Type II latency is exemplified by NPC and Hodg-
kin’s disease. EBNA1, LMP-1, LMP2A, and LMP2B pro-
teins are expressed in type II latency. Type III latency is typ-
ical of early phases of EBV lymphoproliferative syndromes 
and is captured in lymphoblastoid cell lines (LCLs). Nine vi-
ral proteins are expressed, including all six nuclear proteins 
(EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and 
EBNA-LP) and the three integral membrane proteins (LMP-
1, LMP-2A, and LMP-2B) (reviewed in Kieff, 1996 and 
Rickinson and Kieff, 1996).
EBV immortalizes and transforms B cells from cord and 
adult blood into LCLs and concomitantly establishes type 
III latency in vitro. LMP-1 expression is required for the im-
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Abstract
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is required for EBV immortalization of primary B cells in vitro. Signal trans-
ducers and activators of transcription (STATs) play a pivotal role in the initiation and maintenance of certain cancers. STAT proteins, espe-
cially STAT-1, -3, and -5, are persistently tyrosine phosphorylated or activated in many cancers. We show here that EBV-infected type III la-
tency cells, in which the EBV oncoprotein, LMP-1 is expressed, express high levels of four STATs (STAT-1, -2, -3, and -5A) and that LMP-1 is 
responsible for the induction of three (STAT-1, -2, and -3). In addition, the C-terminal activator region 1 (CTAR-1) and CTAR-2 of LMP-1 co-
operatively induced the expression of STAT-1. The cooperativity was evident when CTAR-1 and CTAR-2 were present in cis, but not in trans. 
Furthermore, NF-κB is an essential factor involved in the induction of STAT-1. Most of the induced STATs were not phosphorylated at the crit-
ical tyrosine residue activated by many cytokines. However, the induced STATs, at least STAT-1, were functional because it could be activated 
by interferon (IFN) and could upregulate an IFN-inducible gene. Finally, expression of STAT-1, but not STAT-2 and -3, is associated with EBV 
transformation. The association of the expression of STAT-1, -2, -3, and -5A with EBV type III latency and the expression of STAT-1 in the 
EBV transformation process may be part of the viral programming that regulates viral latency and cellular transformation. 
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mortalization process (Kaye et al., 1993; Kilger et al., 1998). 
LMP-1 can induce a variety of cellular genes that enhance 
cell survival as well as adhesive, invasive, and angiogenic po-
tential (Fries et al., 1996; Henderson et al., 1991; Miller et 
al., 1995; Murono et al., 2001; Wakasaka and Pagano, 2003; 
Wakasaka et al., 2002; Wakasaka et al., 2004; Wang et al., 
1985; Wang et al., 1990a; Yoshizaki et al., 1998).
LMP-1 is an integral membrane protein with six transmem-
brane-spanning domains and a C-terminal domain located in 
the cytoplasm (Kieff, 1996; Liebowitz et al., 1986). LMP-1 
acts as a constitutively active receptor-like molecule that does 
not need a ligand (Gires et al., 1997). The transmembrane do-
mains mediate oligomerization of LMP-1 molecules in the 
plasma membrane, a prerequisite for LMP-1 function (Floett-
mann et al., 1996; Gires et al., 1997). Two regions in its C ter-
minus initiate signaling processes, the C-terminal activator re-
gion 1 (CTAR-1, amino acids 194–231) and CTAR-2 (amino 
acids 332–386) ( Figure 1; Huen et al., 1995; Mitchell and 
Sugden, 1995). 
CTAR-1 is a contributor to the activation of nuclear factor 
κB (NF-κB) by LMP-1. The PXQXT motif localized within 
CTAR-1 is involved in the interaction with tumor necrosis fac-
tor receptor (TNFR)-associated factors (TRAFs). TRAF-1, -2, 
-3, and -5 associate with LMP-1 with different affinities and 
are responsible for NF-κB activation by CTAR-1 (Devergne et 
al., 1996; Devergne et al., 1998; Miller et al., 1997; Sandberg 
et al., 1997). CTAR-1 is responsible for induction of epidermal 
growth factor receptor (EGFR) and TRAF-1 (Devergne et al., 
1998; Miller et al., 1997). CTAR-1 is required for the transfor-
mation of B cells by EBV, and the PXQXT motif is essential 
for this process (Izumi et al., 1997; Kaye et al., 1999).
CTAR-2 is also a contributor to the activation of NF-κB by 
LMP-1. CTAR-2, through its interaction with TNFR-associ-
ated death domain protein (TRADD), activates NF-κB (Izumi 
and Kieff, 1997; Izumi et al., 1999). Also, c-jun N-terminal 
kinase (JNK) and p38 are activated by CTAR-2 (Eliopoulos 
and Young, 1998; Eliopoulos et al., 1999; Kieser et al., 1997). 
The final three amino acids (YYD) play an essential role in 
the signal transduction pathways of CTAR-2.
Interestingly, consensus janus kinase 3 (JAK3) binding 
sites between CTAR-1 and CTAR-2 have been identified (Fig-
ure 1). However, whether JAK3 can bind to these sites and is 
responsible for the activation of signal transducer and activa-
tor of transcription 1 (STAT-1) or other STATs is controversial 
(Brennan et al., 2001; Fielding et al., 2001; Gires et al., 1999; 
Higuchi et al., 2002).
STATs are a family of latent transcription factors that be-
come activated by phosphorylation on a single tyrosine, typi-
cally in response to extracellular ligands (Darnell et al., 1994; 
Stark, 1997). Virtually every cytokine and growth factor can 
cause STAT phosphorylation through receptor or associated 
kinases. Once phosphorylated, STATs can form homo- or het-
erodimers that accumulate in the nucleus, recognize specific 
DNA sequences, and activate transcription (Darnell et al., 
1994; Stark, 1997).
In this report, the relation between EBV and STATs is ex-
amined. We show that high levels of expression of STAT-1, 
-2, -3, and -5A are associated with EBV type III latency in 
which LMP-1 is expressed. LMP-1 stimulates the expres-
sion of STAT-1, -2, and -3, but not STAT-5A. Interestingly, the 
maximum induction of STAT-1 is a result of a cooperative in-
teraction between the LMP-1 CTAR-1 and CTAR-2 domains. 
However, after induction by LMP-1, STAT-1 is not activated 
by phosphorylation. Induction of STATs, especially STAT-
1, -3, and -5A, by EBV may be relevant to viral transforma-
tion processes as well as the pathogenesis of EBV-associated 
tumors.
Results
Expression of STAT-1 is correlated with LMP-1 protein in 
type III latency
We first scanned the expression pattern of STAT-1 in var-
ious EBV-infected cell lines with type I or type III latency 
Figure 1. Molecular structure and locations of functional domains in LMP-1. 
LMP-1 contains a short cytoplasmic amino terminus, a transmembrane hydro-
phobic domain, and a long cytoplasmic carboxy terminus that contains three 
major signaling domains. CTAR-1 mediates interaction with the TRAFs, and 
is the minor NF-κB-activating region. The location of the TRAF-interacting 
motif, PXQXT, is indicated. CTAR-2 is the major NF-κB-activating region. 
Also, CTAR-2 can activate JNK and p38 molecules. Two JAK3-binding sites 
are also indicated; the JAK-STAT pathway might be activated by interaction 
between JAK3 and LMP-1. The amino acid numbers are shown. The draw-
ing is not on scale. 
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profiles. Sav I and Sav III are sister BL lines each derived 
from a single parental cell line. The paired lines differ only 
in their types of latency (Nonkwelo et al., 1996; Zhang and 
Pagano, 1997). The Jijoye (type III) cell line has all the la-
tency genes in its viral genome, whereas its derivative, the 
P3HR1 line, lacks the EBNA-2 gene and a portion of EBNA-
LP (Adldinger et al., 1985). As a result of the deletion, 
P3HR1 cells do not express EBNA-2, and consequently be-
cause EBNA-2 transactivates the LMP-1 promoter (Abbot et 
al., 1990; Ghosh and Kieff, 1990; Tsang et al., 1991; Wang 
et al., 1990b), express a very low level of LMP-1 apparently 
through induction by IRF-7 (Ning et al., 2003). BL41-P3HR1 
and BL41-B95-8 are converted by infection of EBV-negative 
BL41 cells with either P3HR1 or B95-8 virus, respectively 
(Calender et al., 1987). In addition to these paired cell lines, 
other available EBV latently infected cell lines were also ex-
amined. As shown in Figure 2, STAT-1 protein was expressed 
at high levels in type III cell lines with high levels of LMP-1. 
In type I cells in which LMP-1 is not expressed, STAT-1 was 
expressed at much lower levels. These data indicate that the 
expression of STAT-1 correlated with the expression of LMP-
1 in type III latency. 
LMP-1 stimulates the expression of STAT-1 protein
Because EBNA-2 is the primary inducer of LMP-1 mRNA 
(Abbot et al., 1990; Ghosh and Kieff, 1990; Tsang et al., 1991 
and Wang et al., 1990b), and because of the consistent associ-
ation between STAT-1 and LMP-1 expression (Figure 2), it is 
possible that either EBNA-2 and/or LMP-1 are responsible for 
the induction of STAT-1. Both EBV-negative DG75 and EBV-
positive Akata cells were used to determine which viral gene 
could directly induce the expression of STAT-1. LMP-1 or 
EBNA-2 and a CD4-expression plasmid were transfected into 
cells, and the levels of STAT-1 were determined by Western 
blotting after selection of the transfected cells by the use of 
CD-4 antibody-conjugated magnetic beads (see Materials and 
methods). As shown in Figure 3, LMP-1 expression causes a 
marked increase in STAT-1 protein levels in both DG75 and 
Akata cells; however, EBNA-2 seems to have no effect on 
the induction of STAT-1 in DG75 cells. Therefore, LMP-1 is 
probably responsible for the induction of STAT-1 in type III 
latency cells. If EBNA2 is involved in the induction of STATs, 
it is likely to do so indirectly via induction of LMP-1 in EBV-
infected cells. 
LMP-1 induces the expression of STAT-1, STAT-2, and STAT-3
Whether LMP-1 increases STAT-1 at the RNA level was 
examined by RNase Protection Assays (RPA) with specific 
probes. The probe set is capable of detecting RNA of all 
STATs (see “Materials and methods” for details). Pairs of the 
genetically identical Sav I and Sav III cell lines, as well as 
P3HR1 cells and its parental line, Jijoye, were used for the ex-
periments. As shown in Figure 4, STAT-1 RNA levels were 
higher in Sav III and Jijoye lines (lanes 2 and 7). Therefore, 
Figure 2. High expression levels of STAT-1 are associated with the expression of LMP-1. Equal amounts of protein lysates from cell lines were electrophoresed 
in 8% SDS-PAGE and stained with Ponceau S Red after transfer of protein to the membrane. Western blotting with STAT-1, LMP-1, and tubulin antibodies was 
performed simultaneously. The names of cell lines are as labeled. SAV I and SAV III are genetically identical cell lines derived from the same parental line. 
Figure 3. LMP-1 induces the expression of STAT-1 protein. Lysates from 
cells transfected with pcDNA3 (lanes 1 and 3) or LMP-1 expression plasmid 
(lanes 2 and 4), or EBNA2 expression plasmid (lane 5) were used. Western 
blots with STAT-1, LMP-1, EBNA-2, and tubulin antibodies were performed. 
Lanes 1 and 2, Akata cells were used for transfection; lanes 3–5, DG75 cells 
used. The identity of proteins is as shown. 
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STAT-1 RNA expression is also associated with LMP-1 ex-
pression, in agreement with the data in Figure 2. Surprisingly, 
in addition to STAT-1, expression levels of STAT-2, -3, and -
5A RNAs were also higher in type III latency cells (lanes 1, 2, 
6, and 7). STAT-1, -2, -3, and -5A RNAs were also expressed 
at higher levels in CBC/B95-8 (an LCL, type III latency, with 
high level expression of LMP-1) and lower in Eli-BL (type 
I latency, no LMP-1 expression) (data not shown). Thus, the 
expression of STAT-2, -3, and -5A RNAs is also associated 
with type III latency. 
Whether LMP-1 increases STAT RNAs was examined by 
transient transfection of LMP-1 and a CD4-expression plas-
mid into Akata cells and selecting transfected cells as before. 
As shown in Figure 4, LMP-1 expression produces increased 
levels of STAT-1, -2, and -3 RNAs; duplicate results are 
shown in lanes 3 and 4, and lanes 9 and 10. However, LMP-1 
Figure 4. LMP-1 induces the expression of endogenous STAT-1, -2, and -3. (A) LMP-1 induces the expression of endogenous STAT-1, -2, and -3 RNA. Human 
STAT RPA probes were labeled with α-32P-UTP and used for RPA. Lane 11, undigested STATs probes; lanes 1, 2, 6, and 7, RNAs from P3HR1, Jijoye, Sav I and 
Sav III cells, respectively; lane 8, yeast tRNA; lane 5, blank. Lanes 3, 4, 9, and 10, RNAs from transfected and concentrated Akata cells; lanes 3 and 9, pcDNA3; 
lanes 4 and 10, LMP-1 expression plasmid. The identity of the STATs is as indicated. (B) The relative levels of STAT RNAs induced by LMP-1. The autoradiog-
raphy was examined by the Gene Genius Bioimaging System, and the intensity of bands was recorded and analyzed. The results from three independent exper-
iments (two of which are shown in lanes 3, 4, 9, and 10 in panel A) were used for calculations of the induction. STAT-6 was used as an internal control. The rel-
ative levels of STAT-1, -2, -3, and standard deviations are shown. (C) LMP-1 induces the expression of endogenous STAT-2 and -3 proteins. Cell lysates from 
transfected and concentrated Akata cells were used for Western blot analysis. The identity of proteins is as shown. 
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did not increase the expression of STAT-5A RNA (lanes 3, 4, 
9, and 10). The relative STAT RNA levels are shown in Figure 
4B. In addition, we tested if LMP-1 could induce the expres-
sion of STAT-2 and -3 proteins. In Akata cells, both STAT-2 
and -3 are induced by the expression of LMP-1 as shown in 
Figure 4C. In DG75 cells, STAT-2 protein was also efficiently 
induced; however, the induction of STAT-3 protein was not 
very obvious (data not shown). The data together indicate that 
LMP-1 increases the expression of STAT-1, -2, and -3, but not 
STAT-5A.
CTAR-1 and CTAR-2 cooperatively induce the expression of 
STAT-1
Next, the LMP-1 domain requirement for the induction 
of STAT-1 was examined in Akata cells by the use of several 
LMP-1 mutants. Akata cells were used for these experiments 
because STAT-1 is highly inducible in this cell line (Figure 3 
and Figure 4). We tested the role of CTARs in the induction of 
STAT-1 in the context of the whole LMP-1 molecule. LMP-
PQAA has mutations in CTAR1 PXQXT motif that change the 
proline and glutamine into alanines. PQAA mutation in intact 
LMP-1 will knock out the function of the TRAF-interaction 
domain (Devergne et al., 1998; Miller et al., 1998; Sandberg 
et al., 1997). LMP-IID has mutations in the CTAR-2 YYD 
motif that change the two tyrosines into isoleucines. The tyro-
sines (Y) in the last three amino acids of LMP-1 (YYD) have 
been shown to play an important role in the signaling path-
way of CTAR2; mutations of the tyrosine amino acids abol-
ish TRADD binding and the activation of NF-κB and AP-1 by 
the CTAR-2 region (Floettmann and Rowe, 1997; Izumi et al., 
1999; Kieser et al., 1997). LMP-DM has mutations in both 
CTARs (Figure 5A). As shown in Figure 5B, LMP-PQAA or 
LMP-IID induces very marginal levels of STAT-1. When both 
CTARs were mutated in LMP-DM, STAT-1 induction is com-
pletely abolished. Because either CTAR alone only marginally 
induces STAT-1, these data suggest that CTAR1 and CTAR2 
cooperatively induce the expression of STAT-1. 
Whether the full induction of STAT-1 can be complemented 
in trans was examined by co-transfection of individually mu-
tated CTAR-1 and CTAR-2 mutants. As shown in Figure 
5B, co-transfection of LMP-1 plasmids containing individu-
ally mutated CTAR-1 (LMP-PQAA) and CTAR-2 (LMP-IID) 
barely induces STAT-1 and certainly not at a level comparable 
to that induced by LMP-1wt. These data suggest that CTAR1 
and CTAR-2 cooperatively induce STAT-1 only in cis config-
uration, but not in trans.
NF-κB is essential for the induction of STAT-1 by LMP-1
Next, the roles of intracellular molecules involved in the 
induction were examined. Both CTARs can activate NF-κB as 
shown in Figure 6B. In addition, several other molecules have 
been shown to be activated by LMP-1. As shown in Figure 6A, 
LMP-1 alone induced high levels of STAT-1 in either Akata or 
DG75 cells. However, in the presence of superrepressor IκB 
(sr-IκB), the expression of STAT-1 was completely abolished. 
Surprisingly, dominant-negative mutants for TRAFs (TRAF-
1, -2, -3, and -5 DNs) were not able to block the induction of 
STAT-1 efficiently even though the level of LMP-1 expressed 
was similar. In addition, AP-1DN and JAK3DN were not able 
to block the induction (data not shown). 
Because NF-κB is essential for the induction of STAT-1, 
and both CTARs are capable of activating NF-κB, we asked 
whether NF-κB activation might be contributing to the co-
operative induction of STAT-1 by CTAR-1 and -2. As shown 
in Figure 6B, the two CTAR mutations could activate NF-
κB individually as predicted, and the combination of the two 
was able to activate NF-κB to a similar level as wild-type 
LMP-1. These data are in contrast to the requirement for the 
cis configuration of the CTARs for the induction of STAT-1 
and suggest that other factors in addition to NF-κB are also 
involved.
Phosphorylation of Tyrosine 701 in STAT-1 is not detected in 
EBV latency
STAT-1, -3, and -5 are often activated in human cancers. 
Phosphorylation at the critical Tyr-701 residue of STAT-1 is 
a crucial event for its function although the role of activated 
STAT-1 in oncogenesis is not clear yet. We tested the activa-
tion status of STAT-1 by the use of phospho-specific antibod-
Figure 5. Cooperativity between both CTARs is required for efficient in-
duction of STAT-1. (A) Schematic diagram of LMP-1 and its mutants. Solid 
ovals, CTAR1 PXQXT motif; solid bars, CTAR-2 YYD motif. X denotes the 
destruction of the motifs. LMP-PQAA has mutations in the conserved PX-
QXT motif that change the proline and glutamine into alanines. LMP-IID has 
mutations in the CTAR-2 YYD motif that change the two tyrosines into iso-
leucines. LMP-DM has mutations in both CTAR-1 and CTAR-2. (B) Akata 
cells were transfected with pcDNA-3 vector or the various LMP-1 plasmids 
shown in A. The cell lysates were used for Western blot analysis. The identity 
of the proteins is indicated. 
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ies. As shown in Figure 7A, STAT-1 is not phosphorylated, or 
very marginally activated, at the critical Tyr-701 residue in all 
the EBV-positive cell lines tested including Akata, Jijoye, and 
Sav III (lanes 1 and 3, and data not shown). However, STAT-
1 in these cells is capable of being phosphorylated in response 
to IFN-α, suggesting that the STAT-1 is functional (lanes 2 
and 4). We also tested the phosphorylation status of serine 
727 (Ser-727). Interestingly, the STAT-1 Ser-727 is apparently 
constitutively phosphorylated (lanes 5–8). Because Ser-727 is 
also phosphorylated in type I latency cells (data not shown), 
the results suggest that the phosphorylation of Ser-727 is in-
dependent of LMP-1. In addition, the subcellular localization 
of STAT-1 was examined by immunostaining in Jijoye cells, 
in which STAT-1 is highly expressed (Figure 2). Without IFN 
treatment, STAT-1 predominantly localized in the cytoplasm; 
however, STAT-1 was predominantly localized to the nucleus 
upon IFN treatment as predicted (data not shown). It is note-
worthy that we did not observe any phosphorylation and nu-
clear translocation of STAT-1 in LMP-1-transfected human B 
cells (data not shown). 
In addition to phosphorylation of the tyrosine residue, IFN 
can induce its target genes. As shown in Figure 7B, interferon-
stimulated gene 15 (ISG-15) could be induced in all four cell 
lines tested. All these results suggest that STAT-1 in type III 
latency cells is not activated, or very marginally activated, at 
the critical tyrosine residue (Tyr-701). However, the induced 
STAT-1 is functional and capable of responding to IFN.
We also determined the activation status of STAT-3 and -
5, both of which are associated with human cancers. Phos-
pho-STAT-3-specific or phospho-STAT-5-specific antibodies 
were used to determine the activation status of STAT-3 and 
-5. Neither STAT was phosphorylated, or phosphorylated at 
very low levels in type III latency cells. However, STAT-3 
and -5 could be activated by IL-6 (for STAT-3) or IL-2 (for 
STAT-5) (data not shown). These data on the activation sta-
tus of STAT-3 and -5 are in agreement with a recent report 
(Higuchi et al., 2002).
Expression of STAT-1 is associated with EBV transformation
STATs are involved in the pathogenesis of human cancers. 
STATs, especially STAT-1, -3, and -5, are persistently tyro-
sine phosphorylated or activated and play a pivotal role in 
initiation and maintenance of the phenotypes of some cancers 
Figure 6. NF-κB is required for the induction of STAT-1. (A) NF-κB is required for the induction of STAT-1. Akata or DG75 cells were transfected with pcDNA-
3 vector or LMP-1, or LMP-1 plus sr-IκB, or LMP-1 plus a combination of dominant-negative mutants of TRAF-1, -2, -3, and -5 (TRAF DNs). The cell lysates 
were used for Western blot analysis. The identity of proteins is as shown. (B) LMP-1 activates NF-κB activity in Akata cells. Akata cells were transfected with 
NF-κB-reporter construct along with pcDNA-3 or various LMP-1 expression plasmids. Luciferase activities were normalized by β-galactosidase activity. The re-
porter activity is expressed relative to vector control. Standard deviations are shown. 
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(for a review, see Bowman et al., 2000; Bromberg and Dar-
nell, 2000).
EBV can immortalize and transform primary B cells into 
continually growing lymphoblastoid cell lines (LCLs). We 
examined if STATs are associated with this immortalization/
transformation process. The primary B cells were isolated 
from fresh blood by CD-19-conjugated magnetic beads (see 
“Materials and methods” for details). Primary B cells from 
two individuals were compared with four newly transformed 
LCLs. As shown in Figure 8, the expression of STAT-1 is as-
sociated with the EBV immortalization/transformation pro-
cess. Interestingly, expression of STAT-2, -3, and -5A is appar-
ently not associated with this process (Figure 8A). Although 
we have shown clearly that LMP-1 induces STAT-2 and -3, 
CD-19-positive primary B cells are heterogeneous and there-
fore differ from the clonal type I latency and EBV-negative 
Burkitt’s lymphoma cell lines. In addition, it has been docu-
mented that at least one LMP-1-induced gene, Bcl-2, is not 
associated with EBV transformation (Henderson et al., 1991; 
Martin et al., 1993), and we confirmed this observation (Fig-
ure 8A). Thus, STAT-1 is the only one identified that is associ-
ated with EBV transformation. 
Next, we examined if the phosphorylation of STATs is as-
sociated with EBV transformation processes. Because of the 
availability of phospho-STAT antibodies, the phosphorylation 
status of STAT-1, -3, and -5 were examined by Western blot 
Figure 7. Activation status of STAT-1 in EBV-infected cells. (A) Phosphor-
ylation status of STAT-1 in type III latent cells. Western blot with phospho-
specific STAT-1 antibodies was first performed. The membranes were then 
stripped and antibody against intact STAT-1 was used to determine the to-
tal STAT-1 expression. Lanes 2, 5, 6, and 8 are lysates of cells that had been 
treated with IFN-α for 30 min. Lanes 1, 3, 5, and 7 are untreated lysates. Cell 
lines are labeled at the top. (B) ISG-15 is inducible in latent cells. Lysates 
from cells treated with IFN-α (12 h) were used. Western blots with ISG-15 
and tubulin antibodies were performed. The identity of proteins is as shown. 
Figure 8. Expression of STAT-1 is associated with EBV transformation pro-
cesses. (A) STAT-1 expression is induced during the process of immortal-
ization of B lymphocytes by EBV. Primary B cells were isolated from fresh 
blood. Equal amounts of protein lysates from primary B cells and four newly 
transformed LCLs were electrophoresed, and Western blotting with various 
antibodies was performed. The identity of proteins is indicated. (B) STAT-1 is 
not phosphorylated at a critical tyrosine residue during EBV transformation. 
Western blot with phospho-specific (Tyr-701) STAT-1 antibodies was first 
performed. The membranes were then stripped, and antibodies against total 
STAT-1, LMP-1, and tubulin were used to determine expression of these pro-
teins. The positive control is Jijoye cells treated with IFN-α for 30 min. The 
identity of proteins is as shown. 
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analysis. As shown in Figure 8B, STAT-1 was not phosphor-
ylated at the critical Tyr-701 residue. STAT-3 and -5 were not 
activated either (data not shown), in agreement with the recent 
report (Higuchi et al., 2002).
Discussion
EBV has the capability of deregulating B-cell growth 
through activation of endogenous programs of cellular gene 
expression. We show that high levels of STAT-1, -2, -3, and -
5A are associated with EBV type III latency cells. In addition, 
LMP-1, a key type III latency gene, could induce the expres-
sion of STAT-1, -2 and -3; however, it could not induce the 
expression of STAT-5A RNA (Figure 4).
Some genes can be induced by both LMP-1 CTARs, espe-
cially those that are regulated primarily by NF-κB (Mehl et 
al., 2001; Miller et al., 1997; Takeshita et al., 1999). In this 
report, we have shown a cooperative induction of STAT-1 by 
the two CTARs in the cis configuration (Figure 5B). The re-
quirement for efficient induction of STAT-1 by both CTARs 
in cis (Figure 5) is interesting and suggests that LMP-1 in 
vivo might assume a functional conformation maintained 
by both CTARs. The cooperativity is apparently not due to 
the activation of NF-κB because activation of NF-κB by the 
CTARs was not cooperative in the same cells (Figure 6B). 
However, NF-κB is an essential factor for the induction of 
STAT-1 (Figure 6). It is obvious that another factor(s) result-
ing from the cooperation of the two CTARs is also involved 
in the induction of STAT-1. It is somewhat surprising that the 
combination of TRAF DNs including TRAF-1,-2, -3, and -5 
could not efficiently block the induction of STAT-1 (Figure 
6A). Because CTAR-1 is apparently involved in the activa-
tion (Figure 5B), the results also suggest that another TRAF 
member(s), or signaling pathway(s) derived from the TRAF 
binding domain might be responsible for partial induction of 
STAT-1.
LMP-1 has been reported to activate STAT-1 protein by 
phosphorylation via JAK-3 based mainly on studies carried 
out in a fibroblast cell line (Gires et al., 1999). However, we 
examined the STAT-1 and LMP-1 in native environments in 
B cells and found that STAT-1 was not phosphorylated in any 
of the type III cell lines in which both LMP-1 and STAT-1 are 
highly expressed. Also, we did not observe any phosphoryla-
tion and nuclear translocation of STAT-1 by transfecting LMP-
1 into human B cells (data not shown). The difference might 
be due to the cell lines used for the experiments. Activation of 
JAK-3 by LMP-1 might be due to the particular cell line used 
(Higuchi et al., 2002).
Although STATs are mostly in their latent form in EBV la-
tency, these STATs may also have functional roles. A well-
studied example is the ability of latent STAT-1 to regulate os-
teoblast differentiation by attenuating Runx2, an essential 
transcriptional factor in this differentiation process, in the cy-
toplasm (Kim et al., 2003). Another example is low-molecu-
lar weight protein 2 (LMP-2) that is involved in MHC class 
1 processing. Latent nonphosphorylated STAT-1 is able to 
move into the nucleus, bind to DNA, and is responsible for 
the constitutive expression of LMP-2 (Chatterjee-Kishore et 
al., 2000). Also, LMP-1 has been reported to activate a STAT-
responsive element (Fielding et al., 2001; Richardson et al., 
2003); the induction of STAT-1, -2, and -3 could possibly ex-
plain that observation (Figure 4).
In addition, high expression levels of STATs might be re-
lated to the regulation of the EBV BamHI Q latency promoter 
(Qp) which is used for the transcription of EBNA-1 in type 
I latency. Activation of the JAK-STAT pathway has been re-
ported to activate EBV Qp (Chen et al., 1999; Chen et al., 
2003). Because Qp is completely inactive in type III latency, 
and STAT-1, -2, -3, and -5A are highly expressed in type III 
latency, it is unlikely that any of these STATs function to acti-
vate the promoter. Also LMP-1, which is expressed in type III 
latency, represses the activity of Qp reporter constructs as well 
as endogenous Qp activity (Zhang and Pagano, 2000; Zhang 
and Pagano, 2001; Zhang et al., 2001). Therefore, STAT-1, 
-2, -3, and -5A are likely to be repressors of Qp in type III 
latency. In addition, these STATs are not activated in type I 
latency in which Qp is active (data not shown). These obser-
vations led us to test the role of STATs in the regulation of 
Qp. However, STAT-1, -2, and -3, at least in their nonphos-
phorylated state, neither activate nor significantly repress Qp 
in Akata cells (data not shown). It is possible that the activa-
tion of Qp by STATs might only be observable in NPC cells 
(Chen et al., 2003). Thus, our data and published reports sug-
gest that the induced but still latent STATs might be mediators 
that regulate both cellular and EBV genes to the benefit of vi-
ral latency. However, the specific targets of these latent STATs 
are currently unknown.
One of the chief functions of activated STATs is their in-
volvement in the pathogenesis of human cancers. In normal 
cells and in animals, ligand-dependent activation of the STATs 
is a transient process, lasting for several minutes to several 
hours. In contrast, in many cancerous cell lines and tumors, 
where growth-factor dysregulation is frequent, STAT proteins, 
especially STAT-1, -3, and -5, are persistently tyrosine-phos-
phorylated or activated. These activated STAT proteins play a 
pivotal role in initiation and maintenance of the phenotypes of 
some cancers (for a review, see Bowman et al., 2000; Brom-
berg and Darnell, 2000). We have shown in this report that ex-
pression of STAT-1 is associated with the EBV-transformation 
process; however, STAT-2, -3, and -5A are not apparently as-
sociated with immortalization of lymphocytes into cell lines 
(Figure 8). It is also reported that Bcl-2, another LMP-1-in-
ducible gene, is not associated with the EBV transformation 
(Henderson et al., 1991; Martin et al., 1993). Thus, it is ap-
parent that not all LMP-1-inducible genes are associated with 
EBV transformation. We suggest that induction of STATs, es-
pecially STAT-1, by LMP-1 may be a part of the EBV pro-
gramming that regulates viral latency and leads to cellular 
transformation. The overexpression of STAT-1 in EBV trans-
formation may provide a unique scenario that differs from 
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other cancers in which the tyrosine-phosphorylated STATs 
are major factors in oncogenesis. The function of STAT-1 in 
EBV transformation is currently under investigation. Also in-
teresting is that type III latency cells express high levels of 
two interferon regulatory factors (IRF-2 and IRF-7) (Zhang 
and Pagano, 1997; Zhang and Pagano, 1999). It is well known 
that IRFs are involved in the regulation of IFN responsive-
ness (Nguyen et al., 1997; Pitha et al., 1998; Taniguchi et al., 
2001). Thus, it is likely that EBV regulates its latency state by 
the use of two families of proteins involved in the IFN signal-
ing pathway.
In summary, our results expand the role of LMP-1 as a 
pleiotropic molecule in effecting deregulation of cellular 
genes. LMP-1 is now presented as a stimulator of STAT-1, -2, 
and -3 in EBV-infected cells, and NF-κB is an essential fac-
tor for this induction. In addition, the expression of STAT-1 is 
associated with immortalization and transformation of human 
lymphocytes and lymphoblastoid cell lines.
Materials and methods
Cells, plasmids, and antibodies
DG75 is an EBV-negative Burkitt’s lymphoma (BL) cell 
line (Ben-Bassat et al., 1977). Akata, Eli-BL, Rael, Sav I, 
Sav III, P3HR-1, Jijoye, and Raji are all EBV-positive BL 
lines (Adldinger et al., 1985; Calender et al., 1987; Klein et 
al., 1972; Ragona et al., 1980; Rooney et al., 1986; Takada, 
1984). LCC-1 (gift of Dr. Richard Longnecker) and CBC/
B95-8 are EBV-transformed lymphoblastoid cell lines (LCL) 
(Pagano et al., 1992). BL41-P3HR1 and BL41-B95-8 are cell 
lines converted by infection of EBV-negative BL41 BL cells 
with the two different EBV strains (Calender et al., 1987). 
Four newly transformed LCLs (LCL-1, -2, -3, and -4) are gifts 
from Dr. Kenneth Izumi at the University of Texas at San An-
tonio. All cells were maintained in RPMI-1640 plus 10% FBS. 
The fresh blood was purchased from local Red Cross station. 
The CD19-positive primary B cells were isolated from fresh 
PBMC by the use of CD-19 antibody conjugated to magnetic 
beads according to the manufacturer’s recommendation (Dy-
nal, Inc.). The method was used successfully, and the cells 
isolated were infectable by EBV (Sinclair et al., 1994; Sin-
clair et al., 1995).
pcDNA/CD4, pcLMP1, the mutant LMP-1 plasmids 
(LMP-PQAA, LMP-IID, and LMP-DM), EBNA-2 expression 
plasmid, and NF-κB reporter constructs were all described be-
fore (Sung et al., 1991; Zhang and Pagano, 1997; Zhang and 
Pagano, 2000; Zhang and Pagano, 2001; Zhang et al., 2001). 
STAT-1 and STAT-3 expression plasmids were gifts from Dr. 
James Darnell and Dr. Rolf de Groot, respectively. STAT-2 
cDNA was from Dr. James Darnell, and the expression plas-
mid was constructed in pcDNA-3 vector at KpnI and XbaI 
sites. Dominant-negative mutants (DN) for TRAFs (TRAF-
1DN, TRAF-2DN, TRAF-3DN, and TRAF-5DN ), AP-1DN, 
and janus kinase 3 (JAK3) DN were described previously 
(Zhang et al., 2001). The pQ-luc reporter construct has been 
described (Davenport and Pagano, 1999).
LMP-1 monoclonal antibody (CS1-4) and EBNA2 specific 
antibody (PE2) were purchased from Dako. STAT-1 (sc-417, 
sc-591), STAT-2 (sc-1668), STAT-3 (sc-482), and STAT-5A 
(sc-1081) antibodies were purchased from Santa Cruz. Phos-
pho-STAT-3-specific (Tyr-705; #9131) and phospho-STAT-5-
specific (#9351) antibodies were from Cell Signaling Tech-
nology. Phospho-Ser-727 STAT-1 antibody (#06-802) and 
Phospho-Tyr-701 STAT-1 antibody (06-657) were from Up-
state Biotechnology. Tubulin antibody was from Sigma. ISG-
15 antibody was the gift of Dr. Ernest Borden. Interferon α 
(IFN-α) was from Hoffmann La Roche.
Western blot analysis with enhanced chemiluminescence 
(ECL)
Separation of proteins on SDS-PAGE followed standard 
methods. After the proteins were transferred to a nitrocellulose 
or Immobilon membrane, the membrane was blocked with 5% 
non-fat dry milk in TBST (50 mM Tris pH 7.5, 200 mM NaCl, 
0.05% Tween-20) at room temperature for 10 min. It was then 
washed briefly with water and incubated with a primary anti-
body in 5% milk in TBST for 1–2 h at room temperature, or 
overnight at 4 °C. After washing with TBST for 10 min three 
times, the membrane was incubated with the secondary anti-
body at room temperature for 1 h. It was then washed three 
times with TBST as before, treated with ECL (Amersham) or 
SuperSignal (Pierce) detection reagents, and exposed to Ko-
dak XAR-5 film.
Transient transfection, chloramphenicol acetyltransferase 
(CAT) assays, and isolation of transfected cells
107 cells in 0.5 ml medium were used for transfection with 
the use of a BioRad Gene Pulser (320 Volts and 925 μF). Two 
days after transfection, cells were collected for reporter as-
say or for isolation of transfected cells. The luciferase and β-
galactosidase assays were essentially the same as described 
(Zhang et al., 2001).
For isolation of transfected cells, enrichment for CD-4-pos-
itive cells was performed with the use of anti-CD-4-antibody 
conjugated to magnetic beads according to the manufactur-
er’s recommendation (Dynal) as described before (Zhang and 
Pagano, 1999; Zhang and Pagano, 2000; Zhang and Pagano, 
2001; Zhang et al., 2001). The isolated cells were used for the 
extraction of total RNA with the use of RNase Total RNA Iso-
lation Kit (Qiagen) or for Western blot analysis.
RNA extraction and RNase Protection Assays (RPA)
RPA was performed with total RNA with the use of the 
RNase Protection Kit II (Ambion, Inc.). The hybridization 
temperature was 42 °C. The human STAT probe set was pur-
chased from Pharmingen (hSTAT Multi-Probe Template Set, 
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cat# 558834). The probes were generated with the use of T7 
RNA polymerase. RPA autoradiography was analyzed with 
the Syngene Gene Genius Bioimaging System. 
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